← All indications
Glomerulonephritis, IGA
A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE.
Drugs by status
Approved for this indication (4)
Phase 4 trials (27)
- methylprednisolone
- abelmoschus manihot
- corticotropin
- ambrisentan
- prednisone
- betamethasone
- enalapril
- probucol
- hydroxychloroquine
- icosapent ethyl
- olmesartan
- valsartan
- resminostat
- mycophenolate
- aliskiren
- cyclophosphamide
- leflunomide
- calcitriol
- bortezomib
- ramipril
- losartan
- budesonide
- rituximab
- telmisartan
- prednisolone
- azathioprine
- quinapril
Phase 3 trials (13)
Phase 2 trials (23)
Phase 1 trials (8)
Organizations
Organization Involved with Phase 4 Indications (44)
- Genentech
- Biogen
- Novartis
- Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.
- Chong Kun Dang Pharmaceutical
- Baylor University
- Chulalongkorn University
- Cornell University
- Hospital Britanico
- Inje University
- Kyung Hee University
- Kagawa University
- Ohio State University
- Stanford University
- The Rogosin Institute
- University of Milan
- Yonsei University
- Mayo Clinic
- Chinese University of Hong Kong
- Chonbuk National University
- Columbia University
- Peking University
- University of Cagliari
- Zhejiang University
- Tsinghua University
- Jiao Tong University
- Hospital Alessandro Manzoni Lecco
- University of Lyon
- The University of Hong Kong
- Sun Yat-Sen University
- +14 more
Organization Involved with Phase 3 Indications (21)
- Travere
- Anthera Pharmaceuticals
- Kuhnil Pharmaceutical Co., Ltd.
- Mallinckrodt
- Omeros Corporation
- Pronova BioPharma
- University of Arizona
- Central South University
- Anhui Medical University
- China Academy of Chinese Medical Sciences
- Guangxi Medical University
- Guangzhou Medical University
- RWTH Aachen University
- Seoul National University
- Nanchang University
- Zhengzhou University
- University of California, San Francisco
- Government of Korea
- Calliditas Therapeutics
- The First People's Hospital of Yunan Province
- Chinook Therapeutics
Organization Involved with Phase 2 Indications (25)
- Archimedes Pharma Ltd
- Roche
- Astellas
- Merck Serono
- Merck KGaA
- Wyeth
- Alexion
- Alnylam Pharmaceuticals
- Baxalta
- ChemoCentryx
- Ionis Pharmaceuticals, Inc.
- Reata Pharmaceuticals, Inc.
- RemeGen
- Rigel Pharmaceuticals
- Visterra, Inc.
- Apellis Pharmaceuticals, Inc.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Hospital Universitari de Bellvitge
- University of Washington
- University of Leicester
- Uppsala University
- Badalona Hospital Germans Trias i Pujol
- University of Barcelona
- Aravive Biologics
- Travere Therapeutics, Inc.
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (9)